VIR - Infectious Disease Player Vir Biotech Has Limited Near Term Upside Analyst Downgrades | Benzinga
BofA Securities has downgraded Vir Biotechnology Inc (NASDAQ: VIR) to Neutral from Buy with a price target of $14, down from $23.
Analysts Geoff Meacham, Charlie Yang, Susan Chor, Hao Shen, and Alexandria Hammond note that VIR's stock performance YTD has been lackluster, with a decline of 54%, compared to the NBI index's marginal decrease of 4% primarily attributed to disappointing influenza A and HBV data.
However, the analysts maintain a positive outlook on Vir's antibody platform and recognize its long-term potential.
In terms of its pipeline, Vir encountered some challenges in ...